SCHEMBL539077

SCHEMBL539077

CCOC(=O)C(C)CCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.60
TSHR P16473 1/20 0.58
MAPT P10636 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
NPC1 O15118 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
LMNA P02545 1/20 0.49
MMP8 P22894 1/20 0.49
ACE P12821 3/20 0.48
HTT P42858 1/20 0.47
HPGD P15428 1/20 0.47
PIN1 Q13526 1/20 0.47
F10 P00742 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265567 1.00 SMN1; SMN2 (0.60) SMN1; SMN2TSHRMAPTMEN1KMT2A
SCHEMBL8224624 1.00 SMN1; SMN2 (0.60) SMN1; SMN2TSHRMAPTMEN1KMT2A
SCHEMBL6718014 0.90 SMN1; SMN2 (0.54) SMN1; SMN2TSHRMAPTMEN1KMT2A
SCHEMBL15587121 0.90 SMN1; SMN2 (0.54) SMN1; SMN2TSHRMAPTMEN1KMT2A
SCHEMBL15587059 0.90 SMN1; SMN2 (0.54) SMN1; SMN2TSHRMAPTMEN1KMT2A
Phosphine SCHEMBL27419558 0.89 SMN1; SMN2 (0.52) SMN1; SMN2TSHRMAPTMEN1KMT2A
SCHEMBL28578770 0.89 SMN1; SMN2 (0.52) SMN1; SMN2TSHRMAPTMEN1KMT2A
SCHEMBL28329152 0.87 SMN1; SMN2 (0.55) SMN1; SMN2TSHRMAPTMEN1KMT2A
SCHEMBL29232860 0.86 TSHR (0.58) SMN1; SMN2TSHRMEN1KMT2ANPC1
SCHEMBL29006983 0.86 TSHR (0.58) SMN1; SMN2TSHRMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118217-A1 Agonists for Antimicrobial Peptide Systems AKTHELIA PHARMACEUTICALS (IS) 2011-05-19 US claimed
EP-2237684-A2 AGONISTS FOR ANTIMICROBIAL PEPTIDE SYSTEMS Akthelia Pharmaceuticals (IS) 2010-10-13 EP claimed
WO-2009087474-A2 AGONISTS FOR ANTIMICROBIAL PEPTIDE SYSTEMS AKTHELIA PHARMACEUTICALS (IS) 2009-07-16 WO claimed
US-20060292188-A1 Ophthalmic solution with a flavoring agent BAUSCH & LOMB INCORPORATED 2006-12-28 US claimed
WO-2006132870-A1 OPHTHALMIC SOLUTION WITH A FLAVORING AGENT BAUSCH & LOMB INCORPORATED (US) 2006-12-14 WO claimed
EP-2649033-B1 COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONE COMPOUNDS SYTHEON LTD (US) 2018-10-17 EP disclosed
EP-3356356-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 Senomyx, Inc. (US) 2018-08-08 EP disclosed
US-9701177-B2 Ceramic coated automotive heat exchanger components HENKEL AG & CO. KGAA (DE) 2017-07-11 US disclosed
US-20150258047-A1 Therapeutic Compounds AKTHELIA PHARMACEUTICALS (IS) 2015-09-17 US disclosed
US-9078864-B2 Agonists for antimicrobial peptide systems AKTHELIA PHARMACEUTICALS (IS) 2015-07-14 US disclosed
CN-101959429-B Agonists of antimicrobial peptide systems AKTHELIA PHARMACEUTICALS 2014-09-10 CN disclosed
US-20140155358-A1 Therapeutic Compounds AKTHELIA PHARMACEUTICALS (IS) 2014-06-05 US disclosed
US-20080131381-A1 METHODS FOR PHOTOSTABILIZING INGREDIENTS WITHIN COSMETICS, PERSONAL CARE AND HOUSEHOLD PRODUCTS AND COMPOSITIONS OBTAINED THEREFROM MERCK PATENT GESELLSCHAFT (DE) 2008-06-05 US disclosed
US-20070014993-A1 Scented multilayer films and method of making APPLIED EXTRUSION TECHNOLOGIES, INC. 2007-01-18 US disclosed
US-20070014992-A1 Scented multilayer films and method of making LONGMOORE KENNETH J 2007-01-18 US disclosed
US-20060292189-A1 Ophthalmic solution with a flavoring agent as a dosing indicator and method for indicating dosage of an ophthalmic solution BAUSCH & LOMB INCORPORATED 2006-12-28 US disclosed
US-20060292188-A1 Ophthalmic solution with a flavoring agent BAUSCH & LOMB INCORPORATED 2006-12-28 US disclosed
US-7150876-B2 Methods for stabilizing ingredients within cosmetics, personal care and household products MERCK PATENT GMBH (DE) 2006-12-19 US disclosed
US-20050244349-A1 Methods for stabilizing ingredients within cosmetics, personal care and household products SUSONITY Commercial GmbH (DE) 2005-11-03 US disclosed
EP-1591099-A2 Methods for stabilizing ingredients within cosmetics, personal care and household products MERCK PATENT GmbH (DE) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060292188-A1 Ophthalmic solution with a flavoring agent TAS2R60, TAS2R10, TAS2R40 SMN1; SMN2 820/4885TSHR 1000/4885MAPT 678/4885
US-20060292189-A1 Ophthalmic solution with a flavoring agent as a dosing indicator and method for indicating dosage of an ophthalmic solution TAS2R7, TAS2R40, TAS2R42 SMN1; SMN2 573/4885TSHR 984/4885MAPT 1498/4885
US-20110118217-A1 Agonists for Antimicrobial Peptide Systems VIP, GLP1R, MAVS SMN1; SMN2 3320/4885TSHR 2225/4885MAPT 4030/4885
US-20050244349-A1 Methods for stabilizing ingredients within cosmetics, personal care and household products CUTA, TYR, LAGE3 SMN1; SMN2 1823/4885TSHR 4198/4885MAPT 328/4885
US-20150258047-A1 Therapeutic Compounds VIP, CFTR, ATF1 SMN1; SMN2 3945/4885TSHR 943/4885MAPT 900/4885
US-20140155358-A1 Therapeutic Compounds VIP, CFTR, GABBR1 SMN1; SMN2 3869/4885TSHR 1406/4885MAPT 908/4885
US-20080131381-A1 METHODS FOR PHOTOSTABILIZING INGREDIENTS WITHIN COSMETICS, PERSONAL CARE AND HOUSEHOLD PRODUCTS AND COMPOSITIONS OBTAINED THEREFROM TYR, NISCH, PPOX SMN1; SMN2 3270/4885TSHR 4214/4885MAPT 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.